QuarterHawk — Equity ResearchQuarterHawk — Equity Research

Avita Medical Inc. (RCEL)

Healthcare

No action
Fundamental
2
Sentiment
3
Technical
3

Do Nothing: fundamentalScore is 2 (below the required floor of 3); the strategy requires fundamentalScore ≥ 3 before any bullish entry, so no technical setup is staged despite a valid, mixed-to-constructive pullback-in-uptrend chart read.

Analysis as of 2026-11-15· more than 2 trading days ago

Company overview

AVITA Medical, Inc. operates as a therapeutic acute wound care company, providing cell harvesting devices for treating thermal burn wounds and skin defects. Its products include the RECELL System and RECELL GO, among others, serving hospitals and treatment centers across multiple regions.

Fundamental

weak
Fundamental2
Improving but fragile

Revenue growth and margin improvements are overshadowed by negative equity, high debt, and negative cash flow.

Improving but fragile: revenue accelerated 53% in Q3 2026 on an 84% gross margin and the going-concern doubt was formally removed, yet stockholders' equity is negative, the company carries $60 million of 11.5% secured debt, trailing EBITDA and free cash flow are both negative, and the shares trade above consensus analyst targets with a deeply negative DCF. Elevated risk — watchlist, not actionable.

Sentiment

fair
Sentiment3
Constructive but digested

Positive sentiment from recent earnings and regulatory updates is tempered by a lack of upcoming catalysts.

Dominant near-term driver is the rewarded Q3 2026 print (announced, 2026-11-05; +0.60 reception on 53% YoY revenue growth with a raised FY2026 guidance) reinforced by the finalized CMS 2027 RECELL billing framework (announced, +0.50) and a TD Cowen price-target raise to $22 from $20 (2026-11-12); measured media sentiment improved from a +0.13 baseline to +0.55, a determinate positive delta at moderate confidence given only 2 analyzer-scored items in the 14-day window. Red-Flag Screen is clean with no severe or moderate flag fired, but every catalyst is trailing and already largely reflected after a ~329% one-year run with an empty forward calendar, so the setup reads as constructive-but-digested rather than actionably fresh.

Technical

fair
Technical3
Mixed-to-constructive

The stock is in a pullback within a strong primary uptrend, but lacks a fundamental basis for entry.

RCEL is a strong primary uptrend that has entered a four-session corrective pullback. Price 15.63 sits above the SMA50 (13.40, +16.6%) and far above the SMA200 (7.16, +118%), with ADX14 at 36.6, so the larger trend is intact; but price has lost the entire short-term stack — below SMA20 15.83, EMA9 16.33, EMA21 15.60, WMA9 16.54, WMA21 16.18, DEMA14 16.87 and TEMA14 16.65 — after failing at the 18.43 swing high on 2026-11-09. Momentum is cooling rather than broken: RSI14 53.31 is neutral (down from 71.77 on 11-10), Williams %R -74.47 is short-term oversold, and MACD line 0.94 remains above zero but has crossed below its signal (histogram -0.13). Volume is contracting on the slide (497,300 on 11-13 vs 1,137,593 on 11-06), which reads as a healthy pullback rather than distribution. Net: a decent-quality pullback-within-an-uptrend chart — technicalScore 3, mixed short-term, not broken — but the trade is blocked upstream at the fundamental gate (fundamentalScore 2 < 3), so no entry plan is staged.

You’re looking at 2026-11-15 — more than 2 trading days ago.

Subscribers saw this then, and see today’s score, verdict and trade plan now.

Not financial advice. For informational and educational purposes only.